News

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...
Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...
Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...
Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...
The FDA had set an Aug. 19 target action date for the company's application, which was seeking a green light for Eylea HD for the treatment of macular edema following retinal vein occlusion and for ...
Regeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while ...
Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...
Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...
Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...
Sales of EYLEA HD rose to $393 million from $304 million a year earlier thanks to increased demand. EYLEA sales, meanwhile, declined to $754 million from $1.23 billion, which the company attributed to ...
Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country.